ContraVir Pharmaceuticals’ (CTRV) Buy Rating Reaffirmed at Maxim Group
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)‘s stock had its “buy” rating reiterated by equities researchers at Maxim Group in a note issued to investors on Thursday. They presently have a $4.00 price objective on the biopharmaceutical company’s stock.
Shares of ContraVir Pharmaceuticals (CTRV) traded up 0.623% during mid-day trading on Thursday, reaching $0.549. 539,048 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.98. ContraVir Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $2.65. The firm’s market cap is $34.98 million.
A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. raised its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the period. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.